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Abstract
Selection of the optimal surgical and interventional therapies for advanced colorectal cancer liver metas-
tases (CRLM) requires multidisciplinary discussion of treatment strategies early in the trajectory of the
individual patient's care. This paper reports on expert consensus on locoregional and interventional
therapies for the treatment of advanced CRLM. Resection remains the reference treatment for patients
with bilateral CRLM and synchronous presentation of primary and metastatic cancer. Patients with
oligonodular bilateral CRLM may be candidates for one-stage multiple segmentectomies; two-stage
resection with or without portal vein embolization may allow complete resection in patients with more
advanced disease. After downsizing with preoperative systemic and/or regional therapy, curative-intent
hepatectomy requires resection of all initial and currently known sites of disease; debulking procedures
are not recommended. Many patients with synchronous primary disease and CRLM can safely undergo
simultaneous resection of all disease. Staged resections should be considered for patients in whom the
volume of the future liver remnant is anticipated to be marginal or inadequate, who have significant
medical comorbid condition(s), or in whom extensive resections are required for the primary cancer
and/or CRLM. Priority for liver-first or primary-first resection should depend on primary tumour-related
symptoms or concern for the progression of marginally resectable CRLM during treatment of the primary
disease. Chemotherapy delivered by hepatic arterial infusion represents a valid option in patients with
liver-only disease, although it is best delivered in experienced centres. Ablation strategies are not
recommended as first-line treatments for resectable CRLM alone or in combination with resection
because of high local failure rates and limitations related to tumour size, multiplicity and intrahepatic
location.
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Approaches to bilateral colorectal cancer
liver metastases
Historically, criteria for the resectability of colorectal cancer liver
metastases (CRLM) included factors such as a tumour size of
<5 cm, the presence of fewer than four lesions, and unilateral
distribution.1–3 However, contemporary studies show that the
bilateral distribution of CRLM is not an independent predictor of
poor oncologic outcome, but, rather, presents a technical chal-
lenge to the achievement of a margin-negative resection and the
simultaneous preservation of sufficient functional liver paren-
chyma.4 Contemporary consensus supports the suggestion that
ability to remove all metastatic deposits leaving an adequate liver
remnant is key to the definition of resectability.5 Modern chemo-
therapy and biologic agents have further expanded the proportion
of patients with bilateral CRLM eligible for resection by downsiz-
ing tumours; response to chemotherapy is used by many investi-
gators as a surrogate marker of tumour biologic behaviour and
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may have the potential to contribute to selection for hepatectomy
in some patients.6–8
For patients with multiple bilateral CRLM that cannot be
safely or completely resected in a single procedure, two-stage
hepatectomy is a technical approach that has been shown to
accomplish the complete resection of disease that is otherwise
considered unresectable to facilitate longterm survival compara-
ble with that in patients who undergo initial resection.6 These
favourable results are likely, in large part, to reflect selection
because all patients who completed two-stage hepatectomy dem-
onstrated a radiographic and significant histologic response to
chemotherapy. It should be emphasized that an intention-to-
treat analysis which included patients who did not complete all
stages of therapy showed impressive 5-year overall survival supe-
rior to that of matched patients who did respond to chemo-
therapy but did not undergo surgery, further emphasizing the
potential benefit of liver resection in this setting.6 This approach
typically entails initial treatment with systemic chemotherapy
with or without a biologic agent, with reassessment after four to
six chemotherapy cycles. The first-stage resection is typically per-
formed when cross-sectional imaging demonstrates response to
treatment or stable disease. Most commonly, first-stage hepatec-
tomy includes the complete resection of all metastases from the
future liver remnant (FLR) in the form of minor resections that
avoid hepatic pedicle dissection or mobilization of the liver to be
resected in the second stage.9 Portal vein embolization (PVE)
may be required if the FLR volume is insufficient. After 4–6
weeks (without interval chemotherapy), or later (with chemo-
therapy); re-imaging is performed to assess liver regeneration
and second-stage major hepatectomy may be performed, possibly
followed by additional chemotherapy.6
Neither cytotoxic agents nor bevacizumab impair liver regen-
eration after PVE.10,11 In a study by Mentha et al. evaluating
patients undergoing two-stage hepatectomy, mostly without inter-
val chemotherapy, histologic examination demonstrated the
increased proliferation of tumour cells at the periphery of lesions
after second-stage resection.12 Some investigators therefore rec-
ommend interval chemotherapy, whereas others do not in order
to mitigate chemotherapy-associated hepatotoxicity.6,9 If chemo-
therapy is selected, PVE may also be performed during this time
without fear of reduced efficacy.
The in situ split procedure is a recently reported, novel method
for inducing rapid remnant liver hypertrophy by ligating and
dividing the portal vein, and splitting the liver parenchyma along
the intended transection line; a second procedure, to be con-
ducted during the same hospitalization, is required to remove the
specimen once hypertrophy of the liver remnant has occurred.
Recently, Schnitzbauer et al. described this procedure in 25
patients with various malignancies, including 14 with CRLM.13
Although this technique may have a role in selected patients,
enthusiasm must be tempered by the high perioperative mortality
rate of 12% (mainly related to liver failure and infection) and
absence of large studies or longterm results.
One-stage hepatectomy with multiple parenchyma-sparing
resections is widely practised and, when technically feasible, can
be considered a standard approach.14 One-stage hepatectomy
requires high-quality preoperative imaging and mastery of intra-
operative ultrasound and segmental hepatic resections.15 Advan-
tages of one-stage resection include low published morbidity and
mortality rates and the avoidance of a second laparotomy.14 The
selection of a one- or two-stage approach in a patient with bilat-
eral CRLM is challenging and should be individualized based on
disease burden, potential for positive margins, the anatomic dis-
tribution of disease and the nature of any extrahepatic resections
that will be performed. A greater disease burden targeted using
the multiple-wedge approach carries the risk for narrow resection
margins and higher recurrence rates. In a report by Kokudo et al.,
57% of patients with four or more metastases preferentially
treated with one-stage multiple sub-segmentectomies developed
recurrence in the remnant liver.16 However, many patients were
amenable to repeat resection and, in patients with five or more
metastases resected in one to three hepatectomies, 5-year overall
survival after the first hepatectomy was 45%.
The role of ablation as an adjunct to resection in patients with
bilateral CRLM remains controversial.17 Studies combining abla-
tion with resection usually reflect outcomes in patients with more
advanced intrahepatic disease burdens and profiles that many
would consider unresectable, and show 3-year overall survival
rates of 47-51%.17–19 A multi-institution study of 125 patients
who underwent resection with ablation demonstrated median
disease-free and overall survival of 14.7 months and 34.8 months,
respectively, which were shorter than those of patients undergoing
resection alone (median overall survival: 50.5 months).19
However, the two groups were not comparable because patients in
the former were more frequently associated with adverse prognos-
tic factors, including synchronous multinodular bilateral disease.
Intraoperative ablation combined with resection may expand the
number of patients eligible for liver-directed therapy because
normal liver parenchyma can be spared, allowing for contralateral
major resections. Selection for the use of intraoperative ablation is
critical and should be limited to small (3 cm, preferably1 cm)
tumours away from major vessels.20 The short-term benefits of
ablation should thus be balanced with the high longterm risk for
recurrence.
When the disease is refractory to contemporary chemothera-
peutic agents, intra-arterial therapies may downsize metastases
sufficiently to allow resection in some patients.21 However, data are
limited on the safety of hepatectomy after yttrium-90 radioemboli-
zation, which may induce portal hypertension, parenchymal fibro-
sis and liver atrophy. Chemotherapy delivered by hepatic arterial
infusion (HAI) has also been used successfully to convert unresect-
able to resectable disease.22,23 Very advanced disease is the norm in
these patients, who often require ablation combined with resec-
tion, and in whom disease recurrence rates are as high as 90%.22
In patients in whom bilateral CRLM is sufficiently downsized to
allow operative therapy after systemic or intra-arterial therapies,
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resection should encompass all initial sites of disease if possible.
‘Adjuvant hepatectomy’or incomplete removal of just some CRLM
should be avoided because the currently available data do not
demonstrate any oncologic benefit of such an approach.
Consensus statements
1 Resection is the reference standard treatment for bilateral
CRLM.
2 One-stage surgery with multiple resections of multiple bilobar
lesions is an effective strategy with which to treat appropriately
selected patients with bilateral metastases.
3 Two-stage hepatectomy with perioperative chemotherapy 
PVE (or portal vein ligation) may allow the complete resection of
disease in patients who are otherwise considered unresectable.
4 Ablation may be a useful adjunct for managing extensive bilat-
eral CRLM not amenable to complete resection, but proper
selection is critical and higher local recurrence rates must be
recognized.
5 After downsizing with preoperative systemic or intra-arterial
therapy, the goal of a curative-intent hepatectomy remains to
remove all initial and currently known sites of disease if possible.
Incomplete removal of CRLM is not recommended.
Approaches to the synchronous presentation
of colorectal cancer and CRLM
Of the 50% of patients with colorectal cancer (CRC) who
develop liver metastases,24 a large proportion present with syn-
chronous disease.4,25–29 Many studies have found that synchro-
nous CRLM is associated with worse survival than metachronous
disease,1,25,30–33 although others have shown no difference.27,34,35
Patients with synchronous CRLM often have advanced disease
and decisions on their management can be complex, mandating
a multidisciplinary approach that includes the expertise of color-
ectal and hepatic surgeons and medical oncologists. Because the
timing of chemotherapy, hepatic resection and colorectal resec-
tion must be carefully planned and sequenced, it is imperative
that all relevant specialties participate in clinical decision making
from the beginning.
Role and timing of colon and liver resection
One of the main considerations in the management of patients
with synchronous CRLM concerns the roles and timings of resec-
tions of the primary tumour and liver metastases. Resection of the
primary tumour does not improve survival in patients in whom
liver metastases are not resected.36–39 Therefore, among patients
with unresectable CRLM, primary tumour resection is reserved
for patients with symptoms that cannot be controlled with less
invasive techniques such as endoscopic stenting. The reported
5-year survival rates of 40–58% following CRLM resection have
made resection the standard of care in patients who can be ren-
dered disease-free.27,40–42 For patients with initially unresectable
CRLM, systemic chemotherapy is the primary therapy, but the
possibility of reducing the tumour burden sufficiently to allow
resection should always be considered. Adam et al.43 demonstrated
that treatment with FOLFOX [folinic acid (leucovorin), fluorou-
racil (5-FU), oxaliplatin] or FOLFIRI [folinic acid (leucovorin),
5-FU, irinotecan] converted 12.5% of patients with unresectable
CRLM to resectable status. In selected patients, higher rates of
conversion to resectable intrahepatic disease have been reported
after HAI treatment combined with systemic chemotherapy than
after systemic chemotherapy alone.22,23
For patients with a resectable primary tumour and resectable
synchronous CRLM, there are three options in regard to sequenc-
ing the operative components: (i) staged resection with colon
resection first; (ii) staged resection with liver resection first, and
(iii) simultaneous resection of the primary tumour and CRLM.
Regardless of the sequencing of the procedures, in all patients it is
critically important that an adequate oncologic resection at both
sites (liver and primary disease) be performed.
Historically, simultaneous resection was associated with higher
rates of morbidity and mortality and therefore was not advo-
cated.26,31 As a result of continued improvements in anaesthetic
and surgical management, mortality in even major hepatic resec-
tions has decreased to very low rates, prompting many centres
to revisit the safety of simultaneous resection. Thelen and col-
leagues44 reported higher operative mortality after simultaneous
(10%) versus staged (1.1%) resections; all of the lethal events in
the former group occurred after major hepatic resections. By con-
trast, several recent series have reported equal rates of mortality in
simultaneous and staged resections. Yan et al.45 compared out-
comes in 73 patients undergoing simultaneous resection with
those in 30 patients undergoing staged resection and found mor-
tality rates of 0% in both groups, although about three quarters of
patients in both groups were submitted to major hepatic resec-
tion. Martin and colleagues46 reported results in 230 patients in a
contemporary series who underwent resection for synchronous
CRLM (70 simultaneous, 160 staged resections), in whom the
decision on type of resection was based upon the complexity of
the two resections and the overall comorbidity of the patient. The
two groups were equivalent in age and comorbid conditions,
lesion numbers and sizes, and extent of liver resection. The mor-
tality rate was 2% in both groups and complication rates (56%
versus 55%) and the severity of complications were equivalent in
both groups. The simultaneous resection group had a significantly
shorter length of stay (LoS) in hospital compared with the com-
bined lengths of both hospitalizations in the staged resection
group (LoS: 10 days versus 18 days; P = 0.001). Furthermore,
Turrini et al. reported that patients submitted to simultaneous
resection were able to start chemotherapy sooner after surgery and
were more likely to complete the treatment course.47 In a recent
meta-analysis of 14 published reports on 2204 patients, Chen
et al.48 showed that simultaneous resection was associated with a
shorter hospital LoS [weighted mean difference -4.77 days, 95%
confidence interval (CI) -7.26 to -2.28; P < 0.01] and lower mor-
bidity (odds ratio 0.71, 95% CI 0.57–0.88; P = 0.002) compared
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with staged resections, with no difference in longterm survival.
A recent non-randomized study comparing simultaneous versus
staged resection in synchronous CRLM demonstrated equivalent
(or lower) morbidity, equivalent mortality rates, and shorter hos-
pital LoS for simultaneous resection.49
Unfortunately, the studies addressing this particular issue are
limited by a high degree of selection bias arising from the fact that
patients in whom complication rates were expected to be higher
(as a result of greater comorbidity, marginal FLR volume, etc.) are
generally selected for staged resections. The most that can be
concluded from this body of work is that, with careful patient
selection and selective use of PVE, simultaneous colon and liver
resections appear to result in a shorter LoS and equivalent morbid-
ity and mortality rates compared with staged resections. It appears
to be safe to combine a straightforward colon resection (segmental
or hemi-colectomy) with a hepatectomy in which up to four seg-
ments are removed, or minor hepatectomy with any colorectal
resection; in combinations of extended intestinal resections (i.e.
rectal resections, total abdominal colectomy) with major hepatec-
tomy, morbidity risks are significantly greater.50 From a technical
perspective, in patients undergoing simultaneous resection, liver
resection is generally performed first under low central venous
pressure conditions, followed by the colon resection.
In patients who are deemed unsuitable for synchronous resec-
tion, the ‘colorectal-first’ approach has historically been favoured
because of the perceived risks for bleeding, obstruction, perfora-
tion or progression of the primary tumour.44,45,47,48,51 In patients
with haemorrhage or obstruction, resection of the primary
disease should, in nearly all cases, be performed without consid-
ering a simultaneous resection. Likewise, patients who present
with a perforation require urgent surgical intervention, should
almost never undergo simultaneous treatment of the liver disease,
and are at significant risk for peritoneal carcinomatosis that will
mitigate any anticipated benefit of CRLM resection.
An alternative to the synchronous approach and classic
‘colorectal-first’ approach is the ‘liver-first’ approach (or ‘reverse’
approach), initially described by Mentha et al.52 This approach is
useful in patients with a rectal primary tumour, in whom possible
treatments can be sequenced as follows: systemic chemotherapy
first, followed by liver resection, followed by chemoradiation to
the rectal primary tumour, followed by resection of the rectal
primary tumour. The radiation component may be individualized
as the resulting reduction in risk for local recurrence may be
considerably smaller than the risk for distant recurrence.53 The
benefit of this approach is that treatment of the metastatic disease
is not delayed by chemoradiation.52 The ‘liver-first’ approach may
also be useful in advanced CRLM that may progress to become
unresectable while off chemotherapy, although this possibility
should not drive clinical decision making in most patients. Brou-
quet et al. analysed outcomes in 156 patients with synchronous
CRLM who underwent resection via ‘combined’, ‘colorectal-first’
or ‘liver-first’ approaches49 and found that the last of these was
associated with morbidity, mortality and overall survival rates
similar to those of the other strategies. A total of 5% of patients in
the ‘liver-first’ group developed primary tumour-related compli-
cations; all of these patients had demonstrated nearly obstructing
primary tumours prior to chemotherapy. This study showed that
outcomes in patients with colon and rectal primary tumours were
similar regardless of treatment sequence.
The ‘simultaneous’, ‘colorectal-first’ and ‘liver-first’ approaches
all have roles in the treatment of patients with synchronous
CRLM. The particular approach used must be tailored to the
patient through multidisciplinary discussion that prioritizes
therapy for the most pressing disease component, minimizes the
risk for complications and expedites the use of systemic therapy.
Consensus statements
1 Patients with synchronous CRLM should undergo formal
multidisciplinary evaluation by colorectal and hepatic surgeons
and medical oncologists prior to the initiation of any treatment.
2 In many patients with synchronous CRLM, simultaneous
resection by experienced surgeons is feasible, safe and effective;
however, staged resection should be considered for patients
with a marginal or inadequate FLR volume, those with signifi-
cant morbidity-related risks, or when extensive operations are
anticipated at both sites.
3 Priority in staged resections may be given to colorectal-first or
liver-first strategies based on concern for complications related
to the primary tumour or the progression of marginally resect-
able CRLM during treatment of the primary tumour.
Role and timing of chemotherapy in
synchronous CRLM
A more detailed discussion of the timing of chemotherapy
and liver resection (preoperative/neoadjuvant, perioperative,
postoperative/adjuvant) is included in the accompanying third
Expert Consensus Statement presented by Schwarz et al.54 in this
issue of HPB. However, several issues relevant to the treatment of
patients with synchronous CRLM warrant specific discussion.
The concept of selection for resection based on response to
chemotherapy has gained popularity in this group of patients with
CRLM. In the great majority of patients, tumours either decrease
in size or remain stable following treatment with systemic chemo-
therapy, a finding reported in virtually every prospective study
completed using modern chemotherapy.55–58 Response to chemo-
therapy is associated with a lower incidence of non-therapeutic
laparotomy in the prospective European Organization for
Research and Treatment of Cancer (EORTC) study (95%
resected in the chemotherapy arm versus 89% resected in the no-
chemotherapy arm),55 and in multivariate analyses of retrospec-
tive data.59 Conversely, in patients with extensive disease (e.g. four
or more CRLM), progression on chemotherapy is associated
with shorter longterm survival compared with patients with
stable or responding disease (5-year overall survival: 37% in
responders, 30% in patients with stable disease, 8% in patients
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with progression).43 Progression, however, is rare (7% in the
EORTC trial) and progression that precludes resection is even less
common (4%)55 and thus few patients will be denied resection
based on response to chemotherapy.
If chemotherapy is to be given preoperatively, a short course
(four to six cycles) is recommended in view of considerations of
hepatotoxicity.60 Chemotherapy can be safely delivered to patients
with intact primary tumours.49,61 A series of 233 patients [of
whom 78 (33%) had rectal primary lesions] with stage IV CRC
and intact primary tumours treated by systemic chemotherapy
revealed that 11% developed primary tumour-related complica-
tions and 3.5% required a bypass or stoma as a result (other
primary disease-related complications were managed with resec-
tion, stent or radiation).62 When symptoms are minimal or absent,
and when the colonoscope can traverse the lesion, systemic
chemotherapy for synchronous CRLM and untreated primary
tumours can be safely delivered.49,61
Given that the majority of patients respond to chemotherapy
(in both the primary tumour and CRLM), consideration must be
given to marking lesions that might be difficult to locate after a
major chemotherapy response. India ink tattoo of small primary
tumours is recommended to facilitate localization at the time of
resection as some lesions will nearly disappear following short-
course treatment. Similarly, small non-subcapsular liver metas-
tases that would otherwise be amenable to limited liver resection
should be considered for marking (e.g. with a metallic coil by the
interventional radiologist) in case they disappear or become dif-
ficult to localize after systemic therapy.63
For primary tumours that present with minimal bleeding
or demonstrate significant mucosal erosion, treatment with
bevacizumab is not generally recommended for the first cycle(s)
of therapy in view of the risks for bleeding and perforation.64
Development of colonic obstruction in the setting of
chemotherapy-associated neutropenia is associated with signifi-
cant risk for morbidity and mortality, and thus resection of the
primary tumour prior to chemotherapy should be strongly
considered in patients with impending obstruction.49
In conclusion, data from several studies indicate that the
administration of up to six cycles of neoadjuvant FOLFOX is a
reasonable strategy for use in patients with resectable CRLM.
Other data support the safety of chemotherapy in the presence of
an intact primary tumour. A key to this approach involves limiting
pre-resection chemotherapy to 2–3 months to prevent the occur-
rence of chemotherapy-induced liver injury. Patients at interme-
diate or high risk for recurrence (based on the clinical risk score)65
may benefit from preoperative chemotherapy.
Consensus statement
4 In patients with synchronous CRLM and asymptomatic
primary tumours, preoperative chemotherapy (of 2–3 months’
duration) is relatively safe and should be considered in patients
at high risk for recurrent disease.
Intra-arterial therapies
Rationale for hepatic arterial therapy
The liver is the sole site of metastatic disease in many patients with
CRC. Normal liver parenchyma is perfused predominantly by
portal venous blood, whereas metastatic tumours of >1 mm in
size are supplied primarily by the hepatic arterial system.66,67 The
administration of therapy via the hepatic arterial system enhances
drug delivery to tumour tissue and substantially reduces the
occurrence of systemic side-effects.66,67
Hepatic arterial infusion therapy
Hepatic arterial infusion chemotherapy is administered either
through surgically placed ports or through an implantable con-
tinuous infusion pump, both of which provide more durable
delivery than percutaneous catheters.68 Arterial infusion catheters
are best inserted into the gastroduodenal artery.69 Hepatic arterial
infusion pumps are best placed at centres with considerable expe-
rience in this technique by surgeons who have placed at least 25
pumps.70 In this circumstance, complications can be minimized,
and pump function preservation can be as high as 91% at 1 year
and 84% at 2 years.70
Floxuridine is an antimetabolite chemotherapy agent most
commonly used in HAI therapy and is the most thoroughly
studied drug for this purpose. It has a half-life of <10 min and
95% of drug is extracted on its first pass through the liver.71
Radioactive HAI floxuridine distributes a 15-fold higher concen-
tration of chemotherapy to the tumour than to normal liver
parenchyma and a 400-fold higher concentration of chemo-
therapy to the tumour than is observed with systemic administra-
tion.72 5-Fluorouracil (5-FU) has been the preferred agent in
Europe (usually delivered via surgically placed ports)73,74 and
oxaliplatin has been used more recently in HAI therapy with
favourable results.22,75,76
Systemic toxicity is low with HAI-administered floxuridine.
Aberrant gut perfusion can result in ulceration and diarrhoea.77
Biliary toxicity is the most common treatment-related compli-
cation of floxuridine-based HAI chemotherapy and occurs
because the biliary system is also perfused by the hepatic artery.78
Elevated liver enzymes warrant dose modification.79 Simul-
taneous administration of dexamethasone reduces the biliary
toxicity of floxuridine-based HAI.80 The addition of concomitant
systemic chemotherapy can increase the toxicity of HAI pump
therapy.81
Efficacy in unresectable disease
Hepatic arterial infusion chemotherapy has been extensively
studied as first-line treatment for unresectable CRLM in at least
10 randomized studies.82 Although response rates to HAI are
higher than those in non-HAI-treated control subjects, improve-
ments in survival have been inconsistent, with the best being
a 4.4-month advantage in patients treated with floxuridine-
based HAI compared with those receiving systemic 5-FU and
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leucovorin in a well-performed trial conducted by the Cancer
and Leukaemia Group B (CALGB) reported in 2006.83 In this
trial, quality of life in HAI recipients was superior to that in those
treated with systemic therapy only. In the HAI-treated group,
median time to hepatic progression was longer than in the
non-HAI group (9.8 months versus 7.3 months), whereas time to
extrahepatic progression was shorter (7.7 months versus 14.8
months). It is important to note that floxuridine-based HAI was
administered without systemic therapy in this trial, which is not
the current standard approach.
An EORTC trial comparing outcomes in 290 patients on
either systemic therapy or HAI-administered 5-FU and leucovorin
showed no difference in median survival between the groups;
37% of patients in the HAI group received no regional therapy,
underscoring the complexity of this modality.74 A meta-analysis
of 10 selected randomized trials demonstrated a greater tumour
response to HAI therapy than systemic therapy alone (43% versus
18%; P < 0.0001), but no significant overall survival difference
(15.9 months versus 12.4 months; P = 0.24).82 There may be an
advantage to combining HAI with systemic chemotherapy in
patients in whom first-line systemic chemotherapy alone has
failed84 and in a preoperative approach in patients with initially
unresectable disease.23 In the latter scenario, response rates as high
as 92% have been reported.23 A recent French Phase II trial of 26
oxaliplatin-naïve patients with CRLM treated with infusional port
oxaliplatin and systemic 5-FU/leucovorin showed median overall
and disease-free survival of 27 months each.75
Adjuvant approach
Postoperative floxuridine-based HAI (with systemic 5-FU/
leucovorin) following a negative margin hepatic resection has
been compared with i.v. 5-FU/leucovorin alone in a randomized
controlled trial of 156 patients.85 At 2 years, the HAI group had
improved overall survival (86% versus 72%; P = 0.03), but the
10-year follow-up failed to show a sustained, statistically signifi-
cant survival advantage, despite significantly longer progression-
free survival (31.3 months versus 17.2 months; P = 0.02) and
greater overall survival (41% versus 27%; P = 0.10) in the HAI-
treated group.86 No other randomized study to date has shown
HAI chemotherapy to result in a significant survival advantage in
the adjuvant setting. Although limited by the heterogeneity of the
studies it examined, a 2009 Cochrane review of seven randomized
trials of adjuvant HAI of floxuridine or 5-FU therapy for CRLM
failed to show a survival benefit for this therapy over adjuvant
systemic therapy alone.87 A recent Phase II trial conducted
through the National Surgical Adjuvant Breast and Bowel Project
(NSABP) investigated the combination of floxuridine-based HAI
and systemic oxaliplatin and capecitabine in the adjuvant setting
and reported a 2-year survival rate of 85%.88 Studies assessing
the role of HAI chemotherapy in association with modern sys-
temic chemotherapy regimens and different infusional agents are
ongoing.
Consensus statements
1 Hepatic arterial infusion therapy is a promising option for
the provision of palliative or adjuvant therapy in patients with
CRLM, but is best administered in experienced centres.
2 In patients with unresectable CRLM, floxuridine-based HAI
therapy significantly improves tumour response and hepatic
progression-free survival, but the survival advantage of
floxuridine-based HAI over contemporary systemic chemo-
therapy remains questionable.
3 Randomized controlled trials are warranted to examine the
potential advantages of and indications for HAI therapy with
updated systemic chemotherapy regimens in patients with
resectable and unresectable disease.
Radioembolization
Radiotherapy can induce cytotoxicity in malignant liver tumours;
however, the value of standard external beam radiation applied to
hepatic malignancies is limited by toxicity to surrounding hepatic
parenchyma. Radioembolization is a form of brachytherapy in
which a high-energy beta-emitting radiation source (yttrium-90)
is coupled with an appropriately sized (~30 mm diameter) embolic
particle. This technique allows the delivery of a therapeutic dose
to the tumour vasculature and attempts to minimize damage to
uninvolved tissue.89
SIR-Spheres® (Sirtex Medical Pty Ltd, Sydney, NSW, Australia)
are resin-based microspheres approved by the US Food and Drug
Administration (FDA) for use in the treatment of CRLM with
adjuvant intra-arterial floxuridine. The basis of FDA approval was
a Phase III trial of floxuridine-based HAI administered with and
without resin microspheres in 72 patients with unresectable
CRLM.90 The combination therapy was associated with an
improved time to progression (15.9 months versus 9.7 months;
P < 0.01) over floxuridine-based HAI alone. A subsequent multi-
centre Phase II trial of yttrium-90 resin microsphere radioemboli-
zation was performed in 50 patients refractory to chemotherapy
in whom previous oxaliplatin- and irinotecan-based systemic
regimens had failed.91 Response or stable disease was observed
in 48% of patients treated and median overall survival was
12.6 months in these heavily pretreated patients. In this trial
yttrium-90 treatment was well tolerated, although longterm
hepatic toxicity was not evaluated. An ongoing Phase III trial,
SIRFLOX [NCT00724503 (http://www.clinicaltrials.gov)], is eva-
luating yttrium-90 intra-arterial treatment as first-line therapy for
unresectable CRLM treated with FOLFOX6 and SIR-Spheres®
versus FOLFOX6 alone, and is expected to complete in 2012.
TheraSpheres® (MDS Nordion, Ottawa, ON, Canada) are glass-
based microspheres that have a humanitarian device exemption
for the treatment of primary and metastatic liver tumours. There
are limited data on the role of this agent in CRLM. A Phase II trial
of TheraSpheres® as salvage therapy in patients in whom systemic
chemotherapy had failed was performed in 27 patients, with a
positron emission tomography response measured at 88% in the
first treated hepatic lobe.92 A randomized Phase III multicentre
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clinical trial, known as the ‘Efficacy Evaluation of TheraSphere
following Failed First-Line Chemotherapy in Metastatic Colorec-
tal Cancer’ (EPOCH) trial, will open soon at up to 30 sites world-
wide, with a target enrolment of approximately 350 patients
(http://clinicaltrials.gov/ct2/show/NCT01483027).
Consensus statement
4 Yttrium-90 transarterial radioembolization is effective and has
shown promising early results in the palliative management of
unresectable CRLM, and can be considered for patients with
liver-only disease in whom at least one standard line of systemic
chemotherapy fails. First-line therapy with yttrium-90 should
only be administered in clinical trials; longterm toxicity poten-
tial requires further clinical evaluation.
Chemoembolization
The approaches to and reports on traditional transcatheter arte-
rial chemoembolization (TACE) in CRLM are ill-defined and
variable. As such, this discussion will focus on drug-eluting beads
delivering irinotecan (DEBIRI; Biocompatibles UK Ltd, Farnham,
UK), data for which are emerging from ongoing clinical trials.93,94
These are polyvinyl alcohol hydrogel beads loaded with irinote-
can.95 The beads are delivered via a selective transcatheter arterial
administration and lodge in the interface between the tumour and
normal parenchyma. The drug is slowly released into the tumour
environment, providing relatively selective drug exposure. Irinote-
can was selected because of its chemical properties, charge and
ability to be loaded on the beads. An initial experience in 20
patients demonstrated a reduction of >50% in serum carcinoem-
bryonic antigen levels in 12 patients and reduced lesion enhance-
ment on contrasted axial imaging in 80% of patients.96 Right
upper quadrant pain has been the main effect of toxicity.97 Sub-
sequently, a multicentre registry of 55 heavily pretreated patients
reported rates of hepatic progression-free survival and overall
survival at 1 year of 75% for each.98 A Phase II randomized trial of
60 patients comparing treatment with FOLFOX  bevacizumab
plus DEBIRI, with treatment with FOLFOX  bevacizumab
(http://clinicaltrials.gov/ct2/show/NCT00932438) is currently
accruing. Although it is too early to speculate on the benefits of
this therapy, it appears to be well tolerated and offers the potential
for a standardized mode of chemoembolization for CRLM.
Consensus statement
5 Traditional TACE lacks data and standardization as a modality
for treatment of CRLM. DEBIRI is a newer form of TACE,
which shows promising early results, but requires further study
before its use can be recommended.
Ablation strategies including radiofrequency
ablation, microwave ablation and external
beam radiotherapy
Hepatic resection is associated with 5-year survival rates of up
to 58% and cure rates of approximately 20%.27,40,99 Results of this
level are not reported with any other therapy. Local failure at the
resection margin is uncommon, with most large series reporting
rates of significantly <5%.42 Although rates of morbidity in partial
hepatectomy for CRLM have remained stable at 30–40%, 90-day
mortality has diminished substantially to 1% in high-volume
centres.100,101 Furthermore, survival appears to be improving.100
Collectively, these data have established hepatic resection as the
reference standard locoregional treatment for CRLM.
The thermal ablation of tumours utilizes image guidance to
deliver extreme temperatures to a tumour and its surrounding
tissue. The advantages of thermal ablation include its adaptabi-
lity to minimally invasive approaches, the ability to spare liver
parenchyma and a low morbidity rate. Thermal ablation can be
performed percutaneously, laparoscopically or at laparotomy.
At 60 °C there is immediate cell death; typically, ablation zones
are created with temperatures in excess of this threshold. Radio-
frequency ablation (RFA) is the most commonly used form of
thermal ablation in the treatment of liver tumours. In RFA,
needles placed in and around tumours deliver alternating electri-
cal current in the radiofrequency range that generates heat. At
high temperatures, tissue desiccates, limiting current flow and
impairing further ablation.102–104
In properly selected patients, RFA-associated morbidity is gen-
erally <10%, regardless of whether RFA is performed surgically or
percutaneously.105 Mortality in RFA is <1%.105 These advantages
are balanced by a number of limitations to the use of RFA, which
is generally ineffective in tumours of >3 cm in size because of high
local recurrence rates.17,102–104 The heat generated by RFA can
injure adjacent structures (e.g. the diaphragm, gallbladder, gas-
trointestinal tract, major bile ducts) and RFA should not be used
to treat tumours adjacent to these locations. Lastly, the efficacy of
RFA is limited by the presence of large blood vessels as a result of
their high flow and the related ‘heat sink’ effect, which protects
adjacent cells from thermal ablation.102–104 It is therefore impor-
tant to note that unresectable tumours are not generally amenable
to thermal ablation because the factors that make a tumour unre-
sectable (number, size, proximity to major blood vessels or bile
ducts, etc.) also make it unsuitable for ablation.
Local recurrence after RFA remains a major problem. Factors
associated with higher local recurrence rates include large tumour
size, proximity to major blood vessels, diagnosis (CRLM being
worse) and percutaneous approach.20,102–104 In a large meta-
analysis, tumour size and the percutaneous approach were inde-
pendently associated with higher recurrence rates. Recurrence
rates in tumours of >3 cm in size ranged from 25% to 50% regard-
less of approach. For tumours of <3 cm in size, local recurrence
rates in surgical and percutaneous ablation were 4% and 16%,
respectively.20 In single-arm percutaneous RFA series, local recur-
rence rates have ranged from 18% to 50% and are related to
tumour size.20,102–105 Recurrence rates in open RFA have typically
been <15% with some series reporting rates of <10%.20,102–105 The
best local control rates reported for RFA (and other ablation
techniques) appear to be achieved at open operation, probably
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because this allows for the mobilization of the liver and the use of
direct hepatic intraoperative ultrasound to guide probe place-
ment. Intraoperative ablation is also limited by tumour size, as
indicated by recurrence rates of 20% for tumours of 1–3 cm in
size and 50% for tumours of >3 cm in size.106 The utility and
limitations of RFA combined with resection are discussed in the
section entitled ‘Approaches to bilateral colorectal cancer liver
metastases’.
Comparisons between RFA and resection have generally been
limited to retrospective series that have attempted to match
patients. These retrospective comparative studies have shown sub-
stantially higher local recurrence rates for RFA (16–60% versus
0–24%) and better longterm survival in resected patients.102–104
Unfortunately, these comparisons are hampered by tremendous
selection bias and confounding factors, and conclusions about
survival rates are not possible. One recently published study pro-
posed percutaneous RFA as a ‘test of time’ to manage selected
patients with resectable CRLM. In this study, 134 tumours were
treated in 88 patients with limited tumour burdens and >40%
of RFA-treated tumours recurred locally. Resection was not per-
formed in two thirds of patients because they either remained free
of disease (many with repeat RFA) or had unresectable distant
progression.107 In this study, the avoidance of a surgical procedure
was considered the goal of RFA, but whether this should be the
desired outcome is disputable. In this series, RFA failed in >40%
of cases and it was unclear whether patients could be effectively
salvaged. Therefore, this approach has not been uniformly
accepted. Another recent concept refers to the use of laparoscopic
RFA in patients with resectable CRLM. A recent example of such
an approach was illustrated in a study of 64 patients with resect-
able metastases who underwent laparoscopic RFA. Local failure
occurred in 7% of patients and median recurrence-free survival
was 15 months. Median and 5-year actuarial survival were 4.3
years and 49%, respectively, which may be considered comparable
with outcomes in resection series.108 Laparoscopic RFA in well-
selected patients may be a promising strategy, but has not been
sufficiently studied.
Microwave ablation (MWA) is a newer technology that
utilizes high-frequency electromagnetic radiation to create
thermal damage and coagulation necrosis. This form of ablation
carries less risk for charring and a heat sink effect and creates
larger ablation zones more rapidly. As MWA is a more powerful
energy mediator, there are concerns over injury to adjacent struc-
tures. The use of MWA to treat CRLM has not been well studied.
Most series reflect outcomes for a large variety of liver tumours. In
sum, these studies show complication rates ranging from 6% to
30%, with the higher rates occurring in patients undergoing
laparotomy and other procedures.102,109,110 Local recurrence rates
vary hugely from 3% to 50%, but the two largest series reported
low rates of 3% and 6%, respectively.109,110 Published MWA series
report survival rates, but the heterogeneity of diseases treated in
each series precludes the clarification of any conclusions regarding
survival data.102,109,110
External beam radiation therapy (EBRT) has recently been pro-
posed as a potential locoregional therapy in CRLM and other liver
tumours. Historically, EBRT was not used in the liver because the
therapeutic window between its tumoricidal benefits and liver-
specific toxicity was too small. Recent advances in imaging, stere-
otactic body radiation (SBRT) and corrections for respiratory
motion have increased the potential role of EBRT in the treatment
of liver tumours. Furthermore, although it has not been well
studied, EBRT may be effective and safe when used near major
blood vessels; however, the potential for major bile duct toxicity
remains a concern. Overall, the use of SBRT for liver tumours has
been minimally studied and only a few studies have focused on its
use in CRLM. A few well-designed dose-escalation studies have
demonstrated that SBRT can be delivered to liver tumours
without dose-limiting toxicity in doses of 60 Gy. Unfortunately,
local progression rates at 2 years at the initial lower doses have
been high, ranging from 23% to 43%;111–114 higher doses may
afford better local control rates. In a recent dose-escalation study,
nine patients with malignant liver tumours demonstrated a 90%
response rate and a 2-year local control rate of 100% at a dose of
60 Gy in five fractions.114
Consensus statements
1 Ablation strategies are inadequately studied and plagued by
high local failure rates, and are limited by tumour size, tumour
multiplicity and location, and thus are not recommended as
first-line treatments for resectable CRLM.
2 Ablation strategies play a role in highly selected patients with
small, appropriately located tumours when resection is not
feasible or safe, but should be considered as second-line
locoregional therapy to hepatic resection.
3 Prospective trials comparing ablative techniques or comparing
resection with ablation in well-defined patients are needed to
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